Show simple item record

dc.contributor.authorThomson, David J
dc.contributor.authorBeasley, William J
dc.contributor.authorGarcez, Kate
dc.contributor.authorLee, Lip W
dc.contributor.authorSykes, Andrew J
dc.contributor.authorRowbottom, Carl G
dc.contributor.authorSlevin, Nicholas J
dc.date.accessioned2016-04-18T08:47:55Zen
dc.date.available2016-04-18T08:47:55Zen
dc.date.issued2016-03-15en
dc.identifier.citationRelative plan robustness of step-and-shoot vs rotational intensity-modulated radiotherapy on repeat computed tomographic simulation for weight loss in head and neck cancer. 2016: Med Dosimen
dc.identifier.issn1873-4022en
dc.identifier.pmid26993081en
dc.identifier.doi10.1016/j.meddos.2016.01.001en
dc.identifier.urihttp://hdl.handle.net/10541/605644en
dc.description.abstractInterfractional anatomical alterations may have a differential effect on the dose delivered by step-and-shoot intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). The increased degrees of freedom afforded by rotational delivery may increase plan robustness (measured by change in target volume coverage and doses to organs at risk [OARs]). However, this has not been evaluated for head and neck cancer.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Medical dosimetry : official journal of the American Association of Medical Dosimetristsen
dc.titleRelative plan robustness of step-and-shoot vs rotational intensity-modulated radiotherapy on repeat computed tomographic simulation for weight loss in head and neck cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalMedical Dosimetryen
html.description.abstractInterfractional anatomical alterations may have a differential effect on the dose delivered by step-and-shoot intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). The increased degrees of freedom afforded by rotational delivery may increase plan robustness (measured by change in target volume coverage and doses to organs at risk [OARs]). However, this has not been evaluated for head and neck cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record